ProbeChem®
Expedite Your Scientific Research

WWW.PROBECHEM.COM

Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists.

Product Name	:	EVT0185
Cat. No.	:	PC-25220
CAS No.	:	2588489-03-4
Molecular Formula	:	$C_{22}H_{34}O_4$
Molecular Weight	:	362.51
Target	:	ATP Citrate Lyase (ACL, ACLY)
Solubility	:	10 mM in DMSO



CAS: 2588489-03-4

Biological Activity

EVT0185 (EVT-0185) is a novel, orally available small molecule inhibitor of **ATP citrate lyase** (**ACLY**), inhibits de novo lipogenesis with IC50 of 0.46 uM in mouse primary hepatocytes.
EVT0185 is activated in hepatocytes via SLC27A2-dependent conversion to its CoA-thioester form (EVT0185-CoA), allowing liver-specific action while sparing non-hepatic tissues.
EVT0185-CoA directly interacts with the CoA-binding site of ACLY.
EVT0185 more potently inhibits fatty acid and cholesterol synthesis from lactate and acetate than bempedoic acid (Cat#PC-43001) in WT hepatocytes.
EVT0185-CoA inhibits rather than activated AMPKβ1-containing complexes, and also inhibits ACC1, ACC2 and **ACSS2**.
EVT0185 also suppresses clonogenic survival of human (Hep3B) and mouse (Hepa1-6) HCC cell lines more effectively than bempedoic acid.
EVT0185 (100 mg/kg) reduces tumour burden in distinct mouse models of MASH-HCC, promotes tumour-infiltrating B cells.

References

Gautam J, et al. ACLY inhibition promotes tumour immunity and suppresses liver cancer. ***Nature.*** 2025 Jul 30. doi: 10.1038/s41586-025-09297-0.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com